Patent 7655254 was granted and assigned to Intarcia Therapeutics on February, 2010 by the United States Patent and Trademark Office.
An implantable device includes a reservoir containing a suspension of an interferon in an amount sufficient to provide continuous delivery of the interferon at a therapeutically effective rate of 1 ng/day to 600 μg/day to maintain and achieve therapeutic blood or plasma levels of the interferon throughout a substantial period of the administration period.